425 related articles for article (PubMed ID: 31593848)
21. Urine soluble urokinase plasminogen activator receptor as a potential biomarker of lupus nephritis activity.
Burcsár S; Toldi G; Kovács L; Szalay B; Vásárhelyi B; Balog A
Biomarkers; 2021 Jul; 26(5):443-449. PubMed ID: 33825610
[TBL] [Abstract][Full Text] [Related]
22. Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia.
Guo H; Zhou LX; Ma H; Liu B; Cheng J; Ma YY; Zhao L
Oncol Lett; 2017 Jul; 14(1):383-389. PubMed ID: 28693180
[TBL] [Abstract][Full Text] [Related]
23. A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease.
Spinale JM; Mariani LH; Kapoor S; Zhang J; Weyant R; Song PX; Wong HN; Troost JP; Gadegbeku CA; Gipson DS; Kretzler M; Nihalani D; Holzman LB;
Kidney Int; 2015 Mar; 87(3):564-74. PubMed ID: 25354239
[TBL] [Abstract][Full Text] [Related]
24. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.
Yoo TH; Pedigo CE; Guzman J; Correa-Medina M; Wei C; Villarreal R; Mitrofanova A; Leclercq F; Faul C; Li J; Kretzler M; Nelson RG; Lehto M; Forsblom C; Groop PH; Reiser J; Burke GW; Fornoni A; Merscher S
J Am Soc Nephrol; 2015 Jan; 26(1):133-47. PubMed ID: 24925721
[TBL] [Abstract][Full Text] [Related]
25. Soluble urokinase plasminogen activator receptor in type 1 diabetic children, relation to vascular complications.
Sherif EM; El Maksood AAA; Youssef OI; Salah El-Din NY; Khater OKM
J Diabetes Complications; 2019 Sep; 33(9):628-633. PubMed ID: 31301955
[TBL] [Abstract][Full Text] [Related]
26. Osteopontin induces soluble urokinase-type plasminogen activator receptor production and release.
Vaschetto R; Navalesi P; Clemente N; Boggio E; Valsecchi S; Olivieri C; Soluri MF; Kroumova V; Fonio P; Dinatale C; Borrè S; Fortina G; Umberto D; Della Corte F; Chiocchetti A
Minerva Anestesiol; 2015 Feb; 81(2):157-65. PubMed ID: 24994498
[TBL] [Abstract][Full Text] [Related]
27. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
[TBL] [Abstract][Full Text] [Related]
28. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
Sier CF; Stephens R; Bizik J; Mariani A; Bassan M; Pedersen N; Frigerio L; Ferrari A; Danø K; Brünner N; Blasi F
Cancer Res; 1998 May; 58(9):1843-9. PubMed ID: 9581823
[TBL] [Abstract][Full Text] [Related]
29. Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure.
Koch A; Zimmermann HW; Gassler N; Jochum C; Weiskirchen R; Bruensing J; Buendgens L; Dückers H; Bruns T; Gerken G; Neumann UP; Adams DH; Trautwein C; Canbay A; Tacke F
Liver Int; 2014 Oct; 34(9):1330-9. PubMed ID: 24575897
[TBL] [Abstract][Full Text] [Related]
30. The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine.
Scharrenberg JS; Yagdiran A; Brinkmann J; Brune M; Siewe J; Jung N; Mahabir E
J Orthop Surg Res; 2019 Nov; 14(1):367. PubMed ID: 31727136
[TBL] [Abstract][Full Text] [Related]
31. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.
Koch A; Voigt S; Kruschinski C; Sanson E; Dückers H; Horn A; Yagmur E; Zimmermann H; Trautwein C; Tacke F
Crit Care; 2011; 15(1):R63. PubMed ID: 21324198
[TBL] [Abstract][Full Text] [Related]
32. Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD.
Luo S; Coresh J; Tin A; Rebholz CM; Chen TK; Hayek SS; Tracy M; Lipkowitz MS; Appel LJ; Levey AS; Inker LA; Reiser J; Grams ME
Clin J Am Soc Nephrol; 2018 Jul; 13(7):1013-1021. PubMed ID: 29903900
[TBL] [Abstract][Full Text] [Related]
33. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.
Slot O; Brünner N; Locht H; Oxholm P; Stephens RW
Ann Rheum Dis; 1999 Aug; 58(8):488-92. PubMed ID: 10419867
[TBL] [Abstract][Full Text] [Related]
34. Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group.
Sorio C; Mafficini A; Furlan F; Barbi S; Bonora A; Brocco G; Blasi F; Talamini G; Bassi C; Scarpa A
BMC Cancer; 2011 Oct; 11():448. PubMed ID: 21999221
[TBL] [Abstract][Full Text] [Related]
35. Serum levels of soluble urokinase plasminogen activator receptor (suPAR) as a marker of tuberculosis treatment efficacy.
Indumati V; Vijay V; Krishnaswamy D; Rajeshwari V; Ramesh A; Shantala D; Shilpa A
Indian J Tuberc; 2017 Jul; 64(3):206-211. PubMed ID: 28709490
[TBL] [Abstract][Full Text] [Related]
36. Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes.
Harel E; Shoji J; Abraham V; Miller L; Laszik ZG; King A; Dobi D; Szabo G; Hann B; Sarwal MM; Craik CS; Vincenti F
Transplantation; 2020 Jan; 104(1):54-60. PubMed ID: 31449183
[TBL] [Abstract][Full Text] [Related]
37. Soluble Urokinase Receptor and Acute Kidney Injury.
Hayek SS; Leaf DE; Samman Tahhan A; Raad M; Sharma S; Waikar SS; Sever S; Camacho A; Wang X; Dande RR; Ibrahim NE; Baron RM; Altintas MM; Wei C; Sheikh-Hamad D; Pan JS; Holliday MW; Januzzi JL; Weisbord SD; Quyyumi AA; Reiser J
N Engl J Med; 2020 Jan; 382(5):416-426. PubMed ID: 31995687
[TBL] [Abstract][Full Text] [Related]
38. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
[TBL] [Abstract][Full Text] [Related]
39. Serum and Urinary Progranulin in Diabetic Kidney Disease.
Nicoletto BB; Krolikowski TC; Crispim D; Canani LH
PLoS One; 2016; 11(10):e0165177. PubMed ID: 27776152
[TBL] [Abstract][Full Text] [Related]
40. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
Rigolin GM; Tieghi A; Ciccone M; Bragotti LZ; Cavazzini F; Della Porta M; Castagnari B; Carroccia R; Guerra G; Cuneo A; Castoldi G
Br J Haematol; 2003 Mar; 120(6):953-9. PubMed ID: 12648064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
